Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 janv. 2026 08h30 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
21 janv. 2026 04h52 HE | Source: Research and Markets

U.S. Bispecific Antibodies Forecast Report 2025-2033: Market to Grow by Over $260 Billion, Driven by Increased Cancer and Autoimmune Diseases, FDA Approvals, and Strategic Partnerships

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "U.S. Bispecific Antibodies Market Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.The U.S. bispecific antibodies market...
21 janv. 2026 04h14 HE | Source: Research and Markets

Molecular Cytogenetics Market Projecting Strong Growth, Hitting USD 5.41 Billion by 2031

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Molecular Cytogenetics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ...
06 janv. 2026 07h30 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...
05 janv. 2026 10h37 HE | Source: Research and Markets

Precision Medicine Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 1,221 Deals Signed Since 2019 by Company A-Z, Deal Type and Therapy Area

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Precision Medicine Collaboration and Licensing Deals 2019-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a...
16 déc. 2025 08h40 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies,...
10 déc. 2025 10h00 HE | Source: 4D Path

4D Path Collaborates with AMD and Oracle to Scale Predictive Oncology

4D Path has announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials.
03 déc. 2025 10h00 HE | Source: 4D Path

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

Trial analysis published in JNCI predicts residual cancer burden from baseline H&E slides using 4D Path's fully automated, treatment predictive platform
02 déc. 2025 08h00 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...
26 nov. 2025 07h30 HE | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...

Page suivante